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ABSTRACT
The number of patients undergoing percutaneous coronary intervention (PCI) who mandate 
additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy 
(DAPT) is associated with reduced ischemic events including stent thrombosis, myocardial 
infarction and stroke following PCI. However, the tradeoff is an increased risk for bleeding 
while on DAPT. The addition of a novel oral anticoagulant (NOAC) further increases the 
likelihood of bleeding while on antiplatelet therapy. Thus, the overall risks and benefits 
for each patient undergoing PCI on NOAC must be assessed and therapy individualized 
to ensure optimal therapy for each unique situation. Patients on NOAC undergoing PCI 
should undergo routine assessment with intravascular imaging as the role of high-risk 
lesion-related features have increased importance prior to determining optimal duration 
of treatment with DAPT. We review the best practices for the pharmacologic management 
of patients requiring anticoagulation with NOAC who are treated with PCI and require 
antiplatelet therapy.
Keywords: Antiplatelet therapy; Oral anticoagulant; Non-vitamin K antagonist oral 
anticoagulants; Percutaneous coronary intervention
INTRODUCTION
Contemporary percutaneous coronary intervention (PCI) involves placement of a stent 
in the vast majority of cases. This necessitates pharmacotherapy with dual antiplatelet 
therapy (DAPT) following stent implantation. The number of patients undergoing PCI who 
mandate additional oral anticoagulant therapy following stent implantation has been on 
the rise. The addition of oral anticoagulation often requires modification of the antiplatelet 
regimen to optimize patient outcomes by balancing the risk of bleeding with the risk 
for ischemic events. We herein review the current best practices for the pharmacologic 
management of patients requiring anticoagulation with novel oral anticoagulants (NOAC) 
who are treated with PCI.
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POPULATION OF INTEREST
The use of NOAC in patients treated with PCI comprise several indications and occurs 
in approximately 7% of all procedures.1) The most commonly encountered indication for 
anticoagulation is for the prevention of stroke in the setting of atrial fibrillation (AF) with 
an elevated CHA2DS2-VASc score. In 2010, AF affected over 6 million Americans, with 
estimates predicting that by 2050, over 12 million adults in the United States will have AF.2)3) 
Encounters for patients on NOAC in the cardiac catheterization laboratory also occur in 
patients requiring treatment and prevention of venous thromboembolism including deep 
vein thrombosis and pulmonary embolism. Off-label use of NOAC also has been reported for 
the treatment of patients with left ventricular thrombus and for prophylaxis in patients with 
hereditary hypercoagulable disorders.4)5)
NOVEL ORAL ANTICOAGULANTS
NOAC has become widely adopted since initial approval. They represent a class of drugs that 
have two unique mechanisms of action; both directly inhibit a single coagulation factor with 
the distinction between individual types of agents occurring based on the coagulation factor 
that is inhibited. Apixaban, edoxaban and rivaroxaban each inhibit factor Xa, whereas the 
direct thrombin inhibitor dabigatran inhibits factor IIa (thrombin).
An overview of the pivotal NOAC trials in patients with non-valvular AF are summarized in 
Table 1. In the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial, 
dabigatran was compared to warfarin in 18,113 patients with results first published in 2009.6) 
In 2011, results were published from the pivotal Rivaroxaban Once Daily Oral Direct Factor 
Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism 
Trial in AF (ROCKET-AF) trial of 14,246 patients comparing rivaroxaban to warfarin.7) The 
Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF (ARISTOTLE) 
trial compared apixaban to warfarin and assessed outcomes in 18,201 patients.8) Effective 
Anticoagulation with Factor Xa Next Generation in AF (ENGAGE-AF) compared edoxaban to 
warfarin in 21,105 patients with results reported in 2013.9)
The introduction and rise of NOAC were in response to numerous limitations and challenges 
with the pre-existing therapy of vitamin K antagonists (VKA), which requires frequent 
monitoring and has numerous drug and dietary interactions. NOAC provides a potent and 
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Table 1. Pivotal randomized trials comparing NOAC's with warfarin for patients with non-valvular atrial fibrillation
Trial Study drug No. Mean CHA2DS2-VASc score Outcome
RE-LY6) Dabigatran 18,113 2.2 Lower rates of stroke and systemic embolism with dabigatran but similar 
rates of major hemorrhage
ROCKET AF7) Rivaroxaban 14,246 3.5 Rivaroxaban was noninferior to warfarin for the prevention of stroke or 
systemic embolism
There was no difference in the risk of major bleeding; intracranial and fatal 
bleeding however occurred less frequently in the rivaroxaban group
ARISTOTLE8) Apixaban 18,201 2.1 Apixaban was superior to warfarin in preventing stroke or systemic embolism, 
and caused less bleeding and was associated with lower mortality
ENGAGE AF9) Edoxaban 21,105 2.8 Edoxaban was noninferior to warfarin with respect to the prevention of stroke 
or systemic embolism and was associated with lower rates of bleeding and 
death from cardiovascular causes
ARISTOTLE = apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation; ENGAGE AF= effective anticoagulation with factor Xa next 
generation in atrial fibrillation; NOAC = novel oral anticoagulants; RE-LY= Randomized Evaluation of Long-term anticoagulant therapY; ROCKET AF = rivaroxaban 
once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
a predictable therapeutic effect with comparatively minimal routine laboratory monitoring 
required. The class of drugs that comprise NOAC has been alternatively termed direct 
oral anticoagulants as well as a number of other acronyms including target-specific oral 
anticoagulants, oral direct inhibitors, non-VKA oral anticoagulants, and specific oral direct 
anticoagulants. Despite the numerous acronyms proposed, NOAC is the acronym that has 
been favored in society guideline statements.10)11)
HIGH-BLEEDING RISK
While triple therapy with a NOAC and DAPT offers efficacy in the reduction of ischemic 
events, this combination comes at the risk of increased bleeding. A number of clinical 
features contribute to increased bleeding risk. The use of triple therapy on its own increases 
the risk of bleeding, and the duration of triple therapy should be minimized whenever 
possible. Prior history of bleeding, age ≥75 years, heart failure, stroke, abnormal kidney or 
liver function, chronic steroid use, alcohol abuse and malignancy all predispose patients 
to an increased bleeding risk and should all be considered for individualized tailoring of 
the optimal treatment regimen. Additionally, gender, body mass and ethnic differences 
can impact the risk for bleeding on NOAC therapy and may impact the appropriate dose 
selection.12-14)
Multiple risk prediction scores have been introduced to assist in the assessment and 
stratification of bleeding risk. The hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile international normalised ratio, elderly, drugs/
alcohol concomitantly (HAS-BLED) score is among the most commonly used scores for 
bleeding risk stratification and is used to assess bleeding risk in patients with AF. A patient 
with a HAS-BLED score ≥3 is considered to be at high-risk for bleeding.15) The use of the 
HAS-BLED score specifically for patients on concomitant DAPT however has not been 
validated. The PREdicting bleeding Complications In patients undergoing Stent implantation 
and subsEquent (PRECISE)-DAPT score was introduced to assess bleeding risk for patients 
on DAPT. A longer duration of DAPT is associated with significantly increased bleeding 
in patients at high PRECISE-DAPT risk (score≥25).16) Data support an ischemic benefit of 
DAPT only in patients with a PRECISE-DAPT score <25.16) Both bleeding risk prediction 
models have utility for predicting future significant bleeding events in patients taking an oral 
anticoagulants (OAC) and undergoing PCI.17)
BLEEDING AFTER STENT IMPLANTATION
The risk of bleeding in patients on DAPT following PCI remains low but can be significant 
when it occurs. Approximately 4.8% of patients following discharge for PCI required 
bleeding-related readmission in a large analysis from the HMO Research Network-Stent 
(HMORN-Stent) Registry.18) In the Assessment of DAPT with Drug-Eluting Stents (ADAPT-
DES) study, post-discharge bleeding occurred in 6.2% of patients following PCI.19) Significant 
bleeding following PCI is associated with worse long-term clinical outcomes including 
increased mortality.1)18)20) Important racial differences may impact the risk for bleeding with 
DAPT. In a landmark meta-analysis of 7 randomized controlled trials with patient-level data 
for 16,518 patients with varying durations of DAPT following PCI, East Asians had a higher 
probability of bleeding versus ischemia when compared with non-East Asians.14)
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PATIENT-RELATED RISK OF ISCHEMIA
Patient-related risk factors may predispose to major adverse cardiac ischemic events 
following PCI. One of the most critical factors contributing to the necessary minimum 
duration of DAPT and the risk of future ischemic events includes the clinical presentation 
that necessitated the PCI. Patients presenting with ST-elevation-myocardial infarction (MI) 
and acute coronary syndrome typically require DAPT of at least 1 year, whereas PCI for stable 
angina can often be safely managed with DAPT for at least 6 months.
LESION-RELATED ISCHEMIC RISK
It has been standard practice to include patient-level risk for bleeding in the equation of 
decision making for optimal pharmacotherapy regimen. However, it is equally important 
to weigh the risk for ischemic events not just on patient-level risk factors such as diabetes, 
chronic kidney disease and prior stent thrombosis, but also for lesion specific risk factors 
including the anatomical location of the stent, number of stents implanted, total stent 
length, lesion complexity and procedural outcome (Figure 1).
While in 1 analysis of 6 randomized controlled trials, reference vessel diameter was the only 
predictor of target lesion failure, there are several other high-risk lesion-related features 
which have been associated with worse clinical outcomes.21) Stent underexpansion, edge 
dissection and residual reference segment disease play a significant role in the occurrence 
of future ischemic events including stent thrombosis.22) Identification of these risk factors 
is essential to appropriately tailor the optimal duration of DAPT. These features are best 
identified by intravascular imaging, highlighting its importance in any patient being 
considered for early termination of DAPT.23)
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Figure 1. Risk-benefit assessment for individualized approach to pharmacotherapy following PCI. 
PCI = percutaneous coronary intervention.
STENT SELECTION
There is wide variation in practice patterns for antiplatelet therapy and stent selection 
for PCI in patients treated with NOAC's. In a survey of 38 European centers in 2015, just 
12% preferentially prescribed NOAC in patients with non-valvular AF undergoing PCI.24) 
Furthermore, in elective PCI for patients with non-valvular AF and high bleeding risk, the 
majority of respondents favored bare-metal stents (BMS) for stent implantation.
In the Polyzene-F (PzF) SHIELD trial, the novel cobalt-chromium coronary stent with 
specialized PzF coating (COBRA PzF coronary stent; CeleNova Biosciences, San Antonio, 
TX, USA) is associated with favorable target vessel failure at 9-months following 1 month of 
DAPT with no stent thrombosis.25) In the ongoing COBRA REDUCE trial, 996 patients with 
high bleeding risk are being randomized to commercially approved DES with 3 or 6 months 
of DAPT or PCI with COBRA PzF and 14 days of DAPT (NCT02594501).
In the SENIOR trial, 1,200 elderly patients age ≥75 years were randomized to bioresorbable 
polymer DES or BMS. In patients with a similar duration of DAPT, DES reduced the 
occurrence of major adverse cardiac events suggesting even in patients with a high bleeding 
risk, there is limited benefit with BMS.26)
The common practice is to use BMS to be used for patients requiring long-term systemic 
anticoagulation. Currently, it is believed that in patients at high-risk of bleeding, the 
duration of DAPT necessary with contemporary DES is short enough so that DES may be 
used as the primary stent almost universally. This is supported by the 2018 European Society 
of Cardiology (ESC) and the European Association of Cardiovascular Surgery guidelines 
on myocardial revascularization which recommend that new-generation DES should “be 
considered as the default stent type for PCI regardless of clinical presentation, lesion 
subtype, concomitant therapies, or comorbidities” (class I, level of evidence A).27)
While bioresorbable vascular scaffolds (BVS) and drug-coated balloons (DCB) offer potential 
future alternatives to the implantation of DES in patients at high-risk for bleeding to 
minimize necessary post-procedural DAPT, the present data are not sufficient to support 
routine use of BVS or DCB in favor of DES.
DURATION OF DUAL ANTIPLATELET THERAPY
There is wide variation in the duration of required DAPT based on a number of features that 
include balancing patient risk of bleeding and ischemic events, lesion-related risk of ischemic 
events, and stent type. Additionally, significant variation in practice patterns exist worldwide. 
The duration for DAPT can be as short as 2 weeks following stent implantation, as is the case 
with stents such as the COBRA PzF, ranging to as long as lifelong DAPT in patients in whom 
have had vascular brachytherapy. The risk of ischemic events following stent implantation 
is highest immediately after PCI and in the initial weeks afterward. However, the risk of 
bleeding related to DAPT remains relatively constant with time. Therefore, minimizing 
DAPT duration has advantages following the initial post-PCI period. Data supporting 
shorter duration of DAPT (≤6 months) have been increasing.28) Initial results of the short and 
optimal duration of DAPT after everolimus-eluting cobalt-chromium stent-2 (STOPDAPT-2) 
trial suggests that 1-month of DAPT was noninferior to 12-months of DAPT at preventing 
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major adverse ischemic events and superior to 12-months of DAPT at preventing significant 
bleeding.29) Notably, in STOPDAPT-2 intravascular imaging was used almost universally in 
this randomized clinical trial of 3,045 patients.
The GLOBAL LEADERS randomized trial assessed the impact of discontinuation of aspirin 
after 1-month following PCI, followed by antiplatelet monotherapy with ticagrelor compared 
with standard DAPT in 15,991 patients. The investigators reported the experimental single 
antiplatelet therapy arm with ticagrelor alone failed to show superiority for the primary 
endpoint at 2-year follow-up.30) While failing to demonstrate superiority for its primary 
endpoint, the GLOBAL LEADERS study demonstrated the feasibility and safety of an early 
discontinuation of aspirin strategy following PCI, ushering in the way for future studies. 
This will also be investigated in the Ticagrelor With Aspirin or Alone in High-Risk Patients 
After Coronary Intervention (TWILIGHT) trial (NCT02270242) of approximately 9,000 
randomized patients comparing the use of ticagrelor alone versus ticagrelor and aspirin 
together. The impact of these various antiplatelet regimens on bleeding and ischemic events 
at 1-year will be reported. Prolonged DAPT in patients with acute coronary syndrome without 
excessive risk of bleeding should remain the standard of care however due to the increased 
risk of MI with 6-month DAPT based on data from the SMART-DATE randomized trial of 
2,712 patients in Korea.31)
Numerous ongoing pivotal trials are assessing the role of short DAPT therapy following 
DES implantation that will inform optimal practice. In the XIENCE 90 study the safety of 
3-month DAPT in approximately 2,000 patients at high-risk of bleeding is being evaluated 
(NCT03218787). The XIENCE 28 global study will evaluate the safety of 1-month DAPT in 960 
high bleeding risk patients (NCT03355742). Similarly, the Onyx ONE Clear trial is evaluating 
1 month of DAPT treatment following stent implantation in 800 high bleeding risk patients 
(NCT03647475). There is growing evidence that DAPT is required for increasingly shorter 
periods with contemporary DES, and numerous clinical trials are assessing the impact of 
shorter durations of therapy.
ANTIPLATELET AGENT
Aspirin dosing should be low-dose only (≤100 mg daily) for all patients on aspirin therapy 
following PCI.32) Significant variation exists in platelet reactivity for patients on clopidogrel. 
Nearly one-third of patients on clopidogrel have high on-treatment platelet reactivity 
(HTPR) predisposing them to increased ischemic events.33-35) Due to low clinical event 
rates in the Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And 
Safety (GRAVITAS) trial, routine platelet function testing fell out of favor.36)37) This however 
may have increased importance when considering discontinuation of aspirin and using 
monotherapy with clopidogrel.
In the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) 
trial, patients undergoing PCI on maintenance DAPT had platelet function assessed with 
VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA) at the time of PCI. Patients not 
on prior thienopyridine therapy were randomized to clopidogrel or prasugrel and underwent 
P2Y12 platelet function testing. HTPR with P2Y12 reaction units >230 occurred in 51% of 
patients on maintenance clopidogrel (n=192), and 37% of patients that were randomized 
to be loaded with clopidogrel (n=90).38) The EPIPHANY trial highlights the frequency of 
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HTPR in patients treated with PCI, suggesting routine screening in patients who are to be 
considered for antiplatelet monotherapy with clopidogrel alone. Furthermore, the EPIPHANY 
trial supports the role of prasugrel in clopidogrel non-responders.38)39)
There are important ethnic variations in response to antiplatelet agents. In Korean patients 
presenting with acute coronary syndrome, a prospective, observational study of 4,421 patients 
from the Korea Acute MI Registry-National Institute of Health, found that after propensity 
score matching, there was significantly higher in-hospital bleeding complications without a 
reduction in ischemic events with prasugrel compared with clopidogrel.40) Antiplatelet therapy 
in a Korean population with potent antiplatelet agents may still be safe, however may require 
dose adjustment. In the PRASugrel compared to clopidogrel For Japanese PatIenTs with ACS 
undergoing PCI (PRASFIT-ACS) study, reduced dosages of prasugrel was associated with lower 
ischemic events without increased bleeding complications compared to clopidogrel.41) The 
ethnic variation observed with antiplatelet agents highlights that a universal recommendation 
has significant limitations, and optimal treatment regimens should be individualized based on 
the best available data and patient specific factors.
CLINICAL EVIDENCE
The PIONEER AF-PCI trial and the RE-DUAL trial both compared a NOAC plus single 
antiplatelet therapy with triple therapy with a VKA plus DAPT. Both pivotal trials reported 
significantly lower bleeding with the dual antithrombotic regimen compared with triple 
therapy.42-44) In the RE-DUAL trial, dabigatran compared to triple therapy with VKA in 2,725 
randomized patients was associated with a significant reduction of bleeding events at both 150 
mg and 110 mg twice daily dosing with dabigatran.42)43) Due to a concern for potential increased 
risk for ischemic events with the lower dabigatran dose (110 mg twice daily),150 mg twice daily 
dosing with dabigatran is preferred with single antiplatelet therapy. The PIONEER AF-PCI trial 
randomized 2,124 patients with nonvalvular AF treated with PCI to receive 1 of 3 treatment 
strategies of antiplatelet therapy and OAC. The investigators reported that the use of either low-
dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose rivaroxaban plus DAPT 
was associated with lower clinically significant bleeding compared with VKA plus DAPT.44)
The AUGUSTUS trial reported the impact of apixaban with and without aspirin in 4,614 
patients with AF and an acute coronary syndrome or PCI. The use of a P2Y12 inhibitor 
and apixaban without aspirin resulted in less bleeding and fewer hospitalizations without 
significant differences in the incidence of ischemic events compared with drug regimens that 
included a vitamin K antagonist, aspirin, or both.45) Edoxaban is currently being studied as 
part of a triple therapy regimen in the Edoxaban Treatment Versus Vitamin K Antagonist in 
Patients With AF Undergoing PCI (ENTRUST-AF) trial (NCT02866175).
ROLE OF INTRAVASCULAR IMAGING WITH 
PERCUTANEOUS CORONARY INTERVENTION
Studies assessing the impact of intravascular ultrasound (IVUS) on clinical outcomes following 
PCI have consistently demonstrated significant benefit and a reduction in events with 
intravascular imaging.46-49) Ischemic events following PCI can be minimized with intravascular 
imaging, potentially reducing the likelihood of negative impact from interruption in DAPT. 
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Intravascular imaging with either IVUS or optical coherence tomography offers potential 
benefit in this patient population both pre- and post- stent implantation. Pre-PCI intravascular 
imaging is useful for stent sizing and the determination for need for lesion preparation to 
ensure maximal stent expansion.50)51) Post-PCI intravascular imaging can exclude complications 
pre-disposing to ischemic events that may be otherwise not appreciated by angiography alone 
including significant edge dissection, stent underexpansion, and residual disease.52-56) In 
patients in whom a short duration of DAPT is being considered, it is increasingly important for 
procedural optimization with intravascular imaging with final assessment.
GUIDELINE RECOMMENDATIONS
The 2016 American College of Cardiology/American Heart Association (ACC/AHA) 
focused update on duration of DAPT in patients with coronary artery disease guideline 
recommendations for patients at high bleeding risk treated with PCI supports clopidogrel 
as the P2Y12 inhibitor of choice in patients on OAC therapy.57) The duration of DAPT 
recommended by the ACC/AHA guidelines is based on the indication for PCI. In patients 
with stable coronary artery disease, discontinuation of the P2Y12 inhibitor at 3-months is 
recommended, whereas for patients treated for acute coronary syndrome, P2Y12 inhibitors 
should be continued for at least 6 months.57)
The 2018 ESC guidelines similarly recommend clopidogrel as the P2Y12 inhibitor of choice, with 
low dose (≤100 mg daily) aspirin, however recommend keeping the duration of triple therapy 
as short as possible.27) ESC guidelines recommend triple therapy with aspirin, clopidogrel and 
OAC for 1 month, and up to 6 months in patients at higher ischemic risk due to acute coronary 
syndrome or procedural characteristics that outweigh bleeding risk (class IIa, level of evidence 
B).27) When a NOAC is added to either aspirin or clopidogrel, the lowest approved effective dose 
for stroke prevention tested in AF trials should be considered (class IIa, level of evidence C).27) 
The ESC cautions that the use of ticagrelor or prasugrel is not recommended as part of triple 
antithrombotic therapy with aspirin and OAC (class III, level of evidence C).27)
ALGORITHMIC APPROACH
Our recommendation based on current evidenced-based medicine, best practices, clinical 
experience and available pharmacologic therapies is summarized in Figure 2. Prognosis is 
worse in those experiencing an adverse event whether it is an ischemic or bleeding event 
following PCI, so efforts are needed to balance these competing risks.58) Aspirin therapy 
should be limited to low-dose aspirin, and DES should be used as the default choice of stent. 
NOAC's offer significant advantages to VKA including less drug and dietary interactions, 
less routine monitoring of blood work, and greater time in therapeutic range. Potent 
thienopyridine therapy should be used following stent implantation in the absence of routine 
P2Y12 testing prior to initiating antiplatelet monotherapy.
CONCLUSION
DAPT is associated with reduced ischemic events including stent thrombosis, MI and stroke. 
The tradeoff however is an increased risk for bleeding on DAPT. The addition of a NOAC 
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further increases the likelihood of bleeding while on antiplatelet therapy. Thus, the overall 
risks and benefits for each patient undergoing PCI on NOAC's must be assessed and therapy 
individualized to ensure optimal therapy for each unique clinical situation.
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